Interleukin	O
2	O
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	B-protein
proteins	I-protein
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	B-protein
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

While	O
the	O
binding	O
of	O
IL-2	B-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B-protein
,	O
Jak-1	B-protein
and	O
Jak-3	B-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

Since	O
many	O
cytokines	B-protein
that	O
activate	O
Jak	B-protein
kinases	I-protein
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
the	O
ability	O
of	O
IL-2	B-protein
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O

Exposure	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NKL	B-cell_line
)	O
to	O
IL-2	B-protein
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-protein
alpha	I-protein
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B-protein
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B-protein
proteins	I-protein
,	O
p94	B-protein
and	O
p95	B-protein
.	O

p94	B-protein
and	O
p95	B-protein
share	O
homology	O
with	O
Stat1	B-protein
at	O
the	O
phosphorylation	B-protein
site	I-protein
and	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-protein
.	O

These	O
Stat	B-protein
proteins	I-protein
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	B-DNA
DNA	I-DNA
sequence	I-DNA
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	B-protein
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	B-DNA
genes	I-DNA
involved	O
in	O
immune	O
cell	O
function	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

92	NULL
,	NULL
PP-	NULL
7779-7783	NULL
,	NULL
August	NULL
1995	NULL
Biochemistry	NULL
Interleukin	NULL
2	NULL
signaling	NULL
involves	NULL
the	NULL
phosphorylation	NULL
of	NULL
Stat	NULL
proteins	NULL
(	NULL
tyrosine	NULL
phosphorylation	NULL
/cytokine/lymphocyte/natural	NULL
killer	NULL
cell	NULL
)	NULL
DAVID	NULL
A	NULL
.	NULL

Franx*t	NULL
?	NULL

,	NULL
MICHAEL	NULL
J.	NULL
RoBERTSON§	NULL
,	NULL
AzaAD	NULL
BONNIY	NULL
,	NULL
JEROME	NULL
RITZ	NULL
$	NULL
§	NULL
,	NULL
AnD	NULL
MICHAEL	NULL
E.	NULL
GREENBERG*+	NULL
*Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Genetics	NULL
and	NULL
Program	NULL
in	NULL
Neuroscience	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
;	NULL
and	NULL
Divisions	NULL
of	NULL
$	NULL
Hematologic	NULL
Malignancies	NULL
and	NULL
of	NULL
*Medical	NULL
Oncology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
Communicated	NULL
by	NULL
Raymond	NULL
L.	NULL
Erikson	NULL
,	NULL
Harvard	NULL
University	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
,	NULL
April	NULL
25	NULL
,	NULL
1995	NULL
(	NULL
received	NULL
for	NULL
review	NULL
January	NULL
5	NULL
,	NULL
1995	NULL
)	NULL
ABSTRACT	NULL
One	NULL
of	NULL
the	NULL
most	NULL
important	NULL
cytokines	NULL
involved	NULL
in	NULL
immune	NULL
response	NULL
regulation	NULL
is	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
the	NULL
proliferation	NULL
and	NULL
function	NULL
of	NULL
T	NULL
lymphocytes	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

The	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
effects	NULL
of	NULL
IL-2	NULL
are	NULL
propagated	NULL
within	NULL
cells	NULL
are	NULL
not	NULL
understood	NULL
.	NULL

While	NULL
the	NULL
binding	NULL
of	NULL
IL-2	NULL
to	NULL
its	NULL
receptor	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
two	NULL
kinases	NULL
,	NULL
Jak-1	NULL
and	NULL
Jak-3	NULL
,	NULL
subsequent	NULL
steps	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
to	NULL
the	NULL
nucleus	NULL
that	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
specific	NULL
genes	NULL
had	NULL
not	NULL
been	NULL
characterized	NULL
.	NULL

Since	NULL
many	NULL
cytokines	NULL
that	NULL
activate	NULL
Jak	NULL
kinases	NULL
also	NULL
lead	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
members	NULL
of	NULL
the	NULL
Stat	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
IL-2	NULL
to	NULL
trigger	NULL
Stat	NULL
phosphorylation	NULL
was	NULL
examined	NULL
.	NULL

Exposure	NULL
of	NULL
activated	NULL
human	NULL
T	NULL
lymphocytes	NULL
or	NULL
of	NULL
a	NULL
natural	NULL
killer	NULL
cell	NULL
line	NULL
(	NULL
NKL	NULL
)	NULL
to	NULL
IL-2	NULL
leads	NULL
to	NULL
the	NULL
phosphorylation	NULL
of	NULL
Statla	NULL
,	NULL
StatlB	NULL
,	NULL
and	NULL
Stat3	NULL
,	NULL
as	NULL
well	NULL
as	NULL
of	NULL
two	NULL
Stat-related	NULL
proteins	NULL
,	NULL
p94	NULL
and	NULL
p95	NULL
.	NULL

p94	NULL
and	NULL
p95	NULL
share	NULL
homology	NULL
with	NULL
Stat1	NULL
at	NULL
the	NULL
phosphorylation	NULL
site	NULL
and	NULL
in	NULL
the	NULL
Sre	NULL
homology	NULL
2	NULL
(	NULL
SH2	NULL
)	NULL
domain	NULL
,	NULL
but	NULL
otherwise	NULL
are	NULL
immunologically	NULL
distinct	NULL
from	NULL
Stat1l	NULL
.	NULL

These	NULL
Stat	NULL
proteins	NULL
were	NULL
found	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
specific	NULL
DNA	NULL
sequence	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
IL-2	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
may	NULL
activate	NULL
specific	NULL
genes	NULL
involved	NULL
in	NULL
immune	NULL
cell	NULL
function	NULL
.	NULL

The	NULL
human	NULL
immune	NULL
system	NULL
combines	NULL
elements	NULL
of	NULL
both	NULL
an	NULL
antigen-restricted	NULL
response	NULL
by	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
and	NULL
a	NULL
less	NULL
restricted	NULL
response	NULL
by	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
.	NULL

A	NULL
combination	NULL
of	NULL
specific	NULL
antigen	NULL
recognition	NULL
and	NULL
a	NULL
general	NULL
growth	NULL
signal	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
lymphocytes	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
NK	NULL
cell	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
is	NULL
less	NULL
well	NULL
understood	NULL
but	NULL
depends	NULL
,	NULL
in	NULL
part	NULL
,	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
certain	NULL
cytokines	NULL
.	NULL

One	NULL
of	NULL
the	NULL
most	NULL
important	NULL
growth	NULL
and	NULL
activation	NULL
signaling	NULL
molecules	NULL
in	NULL
both	NULL
of	NULL
these	NULL
systems	NULL
is	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
a	NULL
15-kDa	NULL
glycoprotein	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
T-cell	NULL
growth	NULL
factor	NULL
(	NULL
1	NULL
)	NULL
which	NULL
binds	NULL
to	NULL
a	NULL
tripartite	NULL
receptor	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Whereas	NULL
the	NULL
a	NULL
chain	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
is	NULL
necessary	NULL
only	NULL
for	NULL
high	NULL
affinity	NULL
binding	NULL
of	NULL
the	NULL
ligand	NULL
,	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
appear	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
transmitting	NULL
the	NULL
signals	NULL
necessary	NULL
for	NULL
IL-2-dependent	NULL
cellular	NULL
responses	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
how	NULL
the	NULL
binding	NULL
of	NULL
IL-2	NULL
to	NULL
its	NULL
receptor	NULL
leads	NULL
to	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
can	NULL
associate	NULL
with	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
can	NULL
lead	NULL
to	NULL
increased	NULL
phosphorylation	NULL
of	NULL
inositides	NULL
.	NULL

By	NULL
a	NULL
mechanism	NULL
that	NULL
is	NULL
not	NULL
yet	NULL
elucidated	NULL
,	NULL
IL-2	NULL
interaction	NULL
with	NULL
its	NULL
receptor	NULL
also	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
S6	NULL
kinase	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
,	NULL
p56'*	NULL
(	NULL
8	NULL
)	NULL
,	NULL
pS3/p56Y	NULL
``	NULL
(	NULL
9	NULL
)	NULL
,	NULL
Ras	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
Raf	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
and	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
number	NULL
of	NULL
immediate	NULL
early	NULL
genes	NULL
(	NULL
13-15	NULL
)	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
the	NULL
B	NULL
and	NULL
y	NULL
subunits	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
share	NULL
similarity	NULL
with	NULL
other	NULL
receptor	NULL
components	NULL
of	NULL
the	NULL
hema-topoietic	NULL
receptor	NULL
superfamily	NULL
,	NULL
many	NULL
of	NULL
whose	NULL
members	NULL
bind	NULL
to	NULL
and	NULL
activate	NULL
Jak	NULL
kinases	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Recently	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7779	NULL
that	NULL
Jak-3	NULL
and	NULL
Jak-1	NULL
are	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
residues	NULL
and	NULL
show	NULL
enhanced	NULL
kinase	NULL
activity	NULL
in	NULL
vitro	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
(	NULL
17-19	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
Jak	NULL
kinases	NULL
is	NULL
often	NULL
accompanied	NULL
by	NULL
the	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
residues	NULL
of	NULL
a	NULL
group	NULL
of	NULL
cytoplasmic	NULL
proteins	NULL
termed	NULL
Stats	NULL
.	NULL

These	NULL
proteins	NULL
were	NULL
initially	NULL
identified	NULL
by	NULL
virtue	NULL
of	NULL
their	NULL
role	NULL
in	NULL
signaling	NULL
in	NULL
response	NULL
to	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Statl	NULL
is	NULL
produced	NULL
as	NULL
two	NULL
isoforms	NULL
,	NULL
a	NULL
91-kDa	NULL
form	NULL
(	NULL
Statla	NULL
«	NULL
)	NULL
and	NULL
an	NULL
84-kDa	NULL
form	NULL
that	NULL
lacks	NULL
the	NULL
last	NULL
38	NULL
amino	NULL
acids	NULL
(	NULL
Stat1	NULL
$	NULL
)	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Although	NULL
both	NULL
of	NULL
these	NULL
proteins	NULL
can	NULL
bind	NULL
to	NULL
a	NULL
common	NULL
DNA	NULL
element	NULL
,	NULL
only	NULL
Statla	NULL
can	NULL
activate	NULL
transcription	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Upon	NULL
treatment	NULL
with	NULL
IFN-	NULL
«	NULL
,	NULL
both	NULL
of	NULL
these	NULL
proteins	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
distantly	NULL
related	NULL
113-kDa	NULL
protein	NULL
(	NULL
Stat2	NULL
)	NULL
,	NULL
become	NULL
tyrosine	NULL
phosphorylated	NULL
,	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
form	NULL
a	NULL
complex	NULL
that	NULL
can	NULL
bind	NULL
a	NULL
distinct	NULL
DNA	NULL
sequence	NULL
and	NULL
activate	NULL
transcription	NULL
(	NULL
20	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
new	NULL
members	NULL
of	NULL
this	NULL
family	NULL
have	NULL
been	NULL
described	NULL
,	NULL
including	NULL
Stat3	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
,	NULL
Stat4	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
,	NULL
Stat5	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
Stat6	NULL
(	NULL
28	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
there	NULL
are	NULL
other	NULL
members	NULL
of	NULL
this	NULL
family	NULL
whose	NULL
expression	NULL
may	NULL
be	NULL
tissue	NULL
re-stricted	NULL
.	NULL

In	NULL
general	NULL
,	NULL
the	NULL
Stat	NULL
proteins	NULL
are	NULL
located	NULL
in	NULL
the	NULL
cytoplasm	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

Addition	NULL
of	NULL
the	NULL
appropriate	NULL
extracellular	NULL
stimulus	NULL
leads	NULL
to	NULL
Stat	NULL
protein	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
,	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
binding	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
,	NULL
and	NULL
the	NULL
modulation	NULL
of	NULL
transcription	NULL
.	NULL

The	NULL
present	NULL
study	NULL
demonstrates	NULL
that	NULL
both	NULL
Stat	NULL
proteins	NULL
and	NULL
Stat-related	NULL
proteins	NULL
are	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
treatment	NULL
of	NULL
T	NULL
lymphocytes	NULL
or	NULL
NK	NULL
cells	NULL
.	NULL

These	NULL
findings	NULL
delineate	NULL
an	NULL
IL-2-signaling	NULL
pathway	NULL
from	NULL
the	NULL
receptor	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

Human	NULL
IFN-	NULL
«	NULL
was	NULL
provided	NULL
by	NULL
Hoffmann-La	NULL
Roche	NULL
.	NULL

Phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Burroughs	NULL
Wellcome	NULL
.	NULL

Recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
specific	NULL
activity	NULL
1.05	NULL
x	NULL
10°	NULL
units/mg	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Amgen	NULL
.	NULL

Antibodies	NULL
to	NULL
Stat4	NULL
,	NULL
-5	NULL
,	NULL
and	NULL
-6	NULL
were	NULL
purchased	NULL
from	NULL
Transduction	NULL
Laboratories	NULL
(	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
.	NULL

Antibody	NULL
Generation	NULL
.	NULL

A	NULL
peptide	NULL
was	NULL
synthesized	NULL
that	NULL
contained	NULL
amino	NULL
acids	NULL
694-705	NULL
of	NULL
mouse	NULL
Stat1	NULL
,	NULL
with	NULL
phosphotyrosine	NULL
in	NULL
position	NULL
701	NULL
,	NULL
and	NULL
rabbits	NULL
were	NULL
immunized	NULL
with	NULL
a	NULL
peptide-bovine	NULL
serum	NULL
albumin	NULL
conjugate	NULL
.	NULL

Other	NULL
antibodies	NULL
were	NULL
raised	NULL
to	NULL
glutathione	NULL
S-transferase	NULL
fusion	NULL
proteins	NULL
containing	NULL
the	NULL
indicated	NULL
region	NULL
of	NULL
a	NULL
given	NULL
Stat	NULL
protein	NULL
as	NULL
described	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Cells	NULL
.	NULL

NKL	NULL
is	NULL
an	NULL
IL-2-dependent	NULL
,	NULL
neoplastic	NULL
NK	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
CD3~	NULL
CD16+*	NULL
CDS56*	NULL
large	NULL
granular	NULL
lymphocyte	NULL
leukemia	NULL
(	NULL
37	NULL
)	NULL
.	NULL

NKL	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
,	NULL
and	NULL
1	NULL
%	NULL
sodium	NULL
pyruvate	NULL
.	NULL

For	NULL
stimulation	NULL
by	NULL
IL-2	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
Abbreviations	NULL
:	NULL
IL-n	NULL
,	NULL
interleukin	NULL
n	NULL
;	NULL
IFN	NULL
,	NULL
interferon	NULL
;	NULL
PHA	NULL
,	NULL
phyto-hemagglutinin	NULL
;	NULL
NK	NULL
,	NULL
natural	NULL
killer	NULL
.	NULL

*Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Neurology	NULL
,	NULL
Division	NULL
of	NULL
Neuroscience	NULL
,	NULL
Children	NULL
's	NULL
Hospital	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Neurobiology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

7780	NULL
Biochemistry	NULL
:	NULL
Frank	NULL
et	NULL
al	NULL
.	NULL

twice	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
;	NULL
137	NULL
mM	NULL
NaCIl/2.7	NULL
mM	NULL
KCI/10	NULL
mM	NULL
Na	NULL
;	NULL
HPO	NULL
,	NULL
/1.8	NULL
mM	NULL
KH	NULL
;	NULL
PO4	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
medium	NULL
lacking	NULL
IL-2	NULL
for	NULL
8-15	NULL
h	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

SK-MEL-28	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
DMEM	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
were	NULL
isolated	NULL
by	NULL
Ficoll/diatrizoate	NULL
gradient	NULL
centrifugation	NULL
from	NULL
cytophe-resis	NULL
buffy	NULL
coat	NULL
obtained	NULL
from	NULL
healthy	NULL
donors	NULL
.	NULL

Activated	NULL
T	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
culturing	NULL
PBMC	NULL
in	NULL
medium	NULL
containing	NULL
2.5	NULL
ug	NULL
of	NULL
PHA	NULL
per	NULL
ml	NULL
and	NULL
50	NULL
units	NULL
of	NULL
IL-2	NULL
per	NULL
ml	NULL
for	NULL
7-12	NULL
days	NULL
.	NULL

Flow	NULL
cytometry	NULL
revealed	NULL
that	NULL
at	NULL
least	NULL
93	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
T	NULL
cells	NULL
.	NULL

Culture	NULL
medium	NULL
was	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
sodium	NULL
pyruvate	NULL
.	NULL

Whole-Cell	NULL
Extracts	NULL
.	NULL

Following	NULL
stimulation	NULL
,	NULL
cells	NULL
were	NULL
placed	NULL
on	NULL
ice	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
cold	NULL
PBS	NULL
.	NULL

Protein	NULL
was	NULL
extracted	NULL
by	NULL
resuspending	NULL
the	NULL
cells	NULL
to	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
cells	NULL
per	NULL
jl	NULL
in	NULL
extraction	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
TrisHCI	NULL
,	NULL
pH	NULL
8.0/250	NULL
mM	NULL
NaC1/0.5	NULL
%	NULL
Nonidet	NULL
P-40/1	NULL
mM	NULL
sodium	NULL
orthovanadate/10	NULL
ug	NULL
of	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
per	NULL
m1l/10	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
mi/10	NULL
ug	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
)	NULL
on	NULL
ice	NULL
with	NULL
occasional	NULL
vortexing	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Insoluble	NULL
material	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
12,000	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Immunoprecipitation	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Western	NULL
Blotting	NULL
.	NULL

Protein	NULL
samples	NULL
were	NULL
separated	NULL
by	NULL
SDS/	NULL
PAGE	NULL
on	NULL
a	NULL
7	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
blocked	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
primary	NULL
antibody	NULL
diluted	NULL
1:4000	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
incubated	NULL
with	NULL
secondary	NULL
antiserum	NULL
conjugated	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
Calbiochem	NULL
)	NULL
diluted	NULL
1:8000	NULL
.	NULL

Antibody	NULL
binding	NULL
was	NULL
detected	NULL
by	NULL
chemiluminescence	NULL
.	NULL

Anti-phosphotyrosine	NULL
Western	NULL
blots	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
PY20	NULL
(	NULL
ICN	NULL
)	NULL
and	NULL
4G10	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

DNA-Binding	NULL
Assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Two	NULL
microliters	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
mixed	NULL
with	NULL
1	NULL
ng	NULL
of	NULL
P-labeled	NULL
oligonucleotide	NULL
[	NULL
AGCCTGATTTC-CCCGAAATGACGGC	NULL
(	NULL
29	NULL
)	NULL
]	NULL
in	NULL
10	NULL
wl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9/100	NULL
uM	NULL
EGTA/200	NULL
uM	NULL
MgC	NULL
)	NULL
,	NULL
/500	NULL
uM	NULL
dithiothreitol/1	NULL
ug	NULL
of	NULL
bovine	NULL
serum	NULL
albumin/0.2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC-poly	NULL
(	NULL
dI-dC	NULL
)	NULL
per	NULL
ml/1	NULL
%	NULL
Ficoll/O0.1	NULL
ug	NULL
of	NULL
herring	NULL
testis	NULL
DNA	NULL
per	NULL
ml	NULL
)	NULL
.	NULL

The	NULL
incubation	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
.	NULL

For	NULL
antibody	NULL
competition	NULL
,	NULL
antiserum	NULL
was	NULL
added	NULL
(	NULL
1:200	NULL
)	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
.	NULL

The	NULL
products	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
4	NULL
%	NULL
acrylamide	NULL
gel	NULL
in	NULL
0.2	NULL
%	NULL
TBE	NULL
(	NULL
1x	NULL
TBE	NULL
=	NULL
89	NULL
mM	NULL
Tris	NULL
base/89	NULL
mM	NULL
boric	NULL
acid/2	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

RESULTS	NULL
Anti-Phospho-Stat1	NULL
Antibody	NULL
.	NULL

The	NULL
phosphorylation	NULL
of	NULL
Stat1l	NULL
on	NULL
a	NULL
single	NULL
residue	NULL
,	NULL
Tyr-701	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
its	NULL
nuclear	NULL
translocation	NULL
and	NULL
transcriptional	NULL
activation	NULL
(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
phosphorylation	NULL
of	NULL
Statl	NULL
in	NULL
more	NULL
detail	NULL
,	NULL
we	NULL
raised	NULL
antibodies	NULL
that	NULL
specifically	NULL
recognized	NULL
only	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

This	NULL
approach	NULL
held	NULL
the	NULL
possibility	NULL
of	NULL
allowing	NULL
greater	NULL
sensitivity	NULL
in	NULL
detecting	NULL
Stat1l	NULL
phosphorylation	NULL
,	NULL
of	NULL
visualizing	NULL
activation	NULL
of	NULL
Statl	NULL
at	NULL
the	NULL
cellular	NULL
level	NULL
by	NULL
immunocytochemistry	NULL
,	NULL
and	NULL
of	NULL
identifying	NULL
members	NULL
of	NULL
the	NULL
Stat	NULL
family	NULL
that	NULL
shared	NULL
the	NULL
phosphorylation	NULL
site	NULL
of	NULL
Statl	NULL
.	NULL

We	NULL
immunized	NULL
rabbits	NULL
with	NULL
a	NULL
peptide	NULL
containing	NULL
amino	NULL
acids	NULL
694-705	NULL
of	NULL
mouse	NULL
Stat1	NULL
with	NULL
phosphotyrosine	NULL
in	NULL
position	NULL
701	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
this	NULL
serum	NULL
was	NULL
tested	NULL
in	NULL
several	NULL
ways	NULL
.	NULL

Initially	NULL
we	NULL
examined	NULL
IFN-treated	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
pattern	NULL
of	NULL
Stat	NULL
formation	NULL
has	NULL
been	NULL
determined	NULL
.	NULL

When	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
IFN-a	NULL
,	NULL
Stat1a	NULL
,	NULL
Stat1B	NULL
,	NULL
and	NULL
Stat2	NULL
become	NULL
phosphorylated	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
human	NULL
melanoma	NULL
cells	NULL
(	NULL
SK-MEL-28	NULL
)	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
antibody	NULL
91/84	NULL
,	NULL
which	NULL
recognizes	NULL
amino	NULL
acids	NULL
598-705	NULL
shared	NULL
by	NULL
Statle	NULL
and	NULL
Stat1l	NULL
$	NULL
B	NULL
.	NULL

This	NULL
revealed	NULL
two	NULL
bands	NULL
in	NULL
untreated	NULL
cells	NULL
of	NULL
molecular	NULL
masses	NULL
91	NULL
and	NULL
84	NULL
kDa	NULL
that	NULL
represent	NULL
Statla	NULL
and	NULL
Stat1	NULL
$	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
1	NULL
)	NULL
.	NULL

Upon	NULL
treatment	NULL
with	NULL
IFN-a	NULL
,	NULL
an	NULL
additional	NULL
band	NULL
of	NULL
apparent	NULL
molecular	NULL
mass	NULL
92	NULL
kDa	NULL
can	NULL
be	NULL
seen	NULL
.	NULL

This	NULL
represents	NULL
the	NULL
Tyr-701-phosphorylated	NULL
form	NULL
of	NULL
Stat1a	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Although	NULL
Stat1	NULL
B	NULL
also	NULL
becomes	NULL
phosphorylated	NULL
,	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
phosphorylated	NULL
form	NULL
is	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
the	NULL
unphosphor-ylated	NULL
form	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
anti-phospho-Statl	NULL
serum	NULL
,	NULL
this	NULL
blot	NULL
was	NULL
then	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
the	NULL
anti-phospho-Stat1	NULL
serum	NULL
.	NULL

This	NULL
antibody	NULL
recognized	NULL
no	NULL
bands	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
in	NULL
the	NULL
IFN-	NULL
«	NULL
~-treated	NULL
cells	NULL
,	NULL
it	NULL
recognized	NULL
bands	NULL
corresponding	NULL
to	NULL
phosphorylated	NULL
Statla	NULL
«	NULL
a	NULL
and	NULL
phosphorylated	NULL
StatlB	NULL
,	NULL
with	NULL
a	NULL
10-fold	NULL
greater	NULL
sensitivity	NULL
than	NULL
that	NULL
of	NULL
antibody	NULL
91/84	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Phosphorylated	NULL
Stat2	NULL
,	NULL
which	NULL
does	NULL
not	NULL
share	NULL
homology	NULL
with	NULL
Statl	NULL
at	NULL
its	NULL
phosphorylation	NULL
site	NULL
,	NULL
was	NULL
not	NULL
recognized	NULL
by	NULL
this	NULL
antiserum	NULL
.	NULL

That	NULL
this	NULL
serum	NULL
is	NULL
recognizing	NULL
Stat1	NULL
was	NULL
further	NULL
shown	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
immunoprecipitate	NULL
tyrosine-phosphorylated	NULL
Stat1	NULL
only	NULL
from	NULL
IFN-a-treated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
in	NULL
immunocytochemistry	NULL
,	NULL
this	NULL
antibody	NULL
stained	NULL
the	NULL
nuclei	NULL
of	NULL
IFN-treated	NULL
cells	NULL
but	NULL
showed	NULL
no	NULL
staining	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
anti-phospho-Statl	NULL
antiserum	NULL
specifically	NULL
recognizes	NULL
only	NULL
the	NULL
tyrosine-phosphorylated	NULL
form	NULL
of	NULL
Statl	NULL
.	NULL

Stats	NULL
Phosphorylated	NULL
in	NULL
Response	NULL
to	NULL
IL-2	NULL
.	NULL

To	NULL
explore	NULL
Stat	NULL
phosphorylation	NULL
upon	NULL
treatment	NULL
with	NULL
IL-2	NULL
,	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
PHA-stimulated	NULL
human	NULL
T	NULL
cells	NULL
or	NULL
NKL	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
by	NULL
using	NULL
the	NULL
antibody	NULL
that	NULL
specifically	NULL
recognizes	NULL
the	NULL
tyrosine-phosphorylated	NULL
form	NULL
of	NULL
Stat1	NULL
.	NULL

Within	NULL
minutes	NULL
of	NULL
IL-2	NULL
treatment	NULL
,	NULL
four	NULL
bands	NULL
could	NULL
be	NULL
detected	NULL
with	NULL
the	NULL
anti-phospho-Stat1l	NULL
antiserum	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

A	NULL
band	NULL
of	NULL
molecular	NULL
mass	NULL
84	NULL
kDa	NULL
that	NULL
comigrates	NULL
with	NULL
phosphorylated	NULL
Stat1B	NULL
detected	NULL
in	NULL
IFN-	NULL
«	NULL
-treated	NULL
cells	NULL
appeared	NULL
within	NULL
1	NULL
min	NULL
of	NULL
stimulation	NULL
,	NULL
reached	NULL
maximal	NULL
intensity	NULL
at	NULL
15	NULL
min	NULL
,	NULL
and	NULL
could	NULL
no	NULL
longer	NULL
be	NULL
detected	NULL
by	NULL
60	NULL
min	NULL
.	NULL

A	NULL
band	NULL
of	NULL
molecular	NULL
mass	NULL
92	NULL
kDa	NULL
that	NULL
comigrates	NULL
with	NULL
phosphorylated	NULL
Stat1a	NULL
appeared	NULL
at	NULL
near	NULL
maximal	NULL
intensity	NULL
by	NULL
1	NULL
min	NULL
and	NULL
was	NULL
no	NULL
longer	NULL
detectable	NULL
by	NULL
60	NULL
min	NULL
.	NULL

Two	NULL
bands	NULL
that	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
IFN-a-treated	NULL
cells	NULL
,	NULL
of	NULL
molecular	NULL
masses	NULL
94	NULL
and	NULL
95	NULL
kDa	NULL
were	NULL
also	NULL
seen	NULL
.	NULL

The	NULL
94-kDa	NULL
band	NULL
,	NULL
which	NULL
is	NULL
the	NULL
predominant	NULL
species	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
reached	NULL
maximal	NULL
intensity	NULL
by	NULL
15	NULL
min	NULL
and	NULL
persisted	NULL
for	NULL
at	NULL
least	NULL
5	NULL
h	NULL
after	NULL
IL-2	NULL
treatment	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
a	NULL
fainter	NULL
95-kDa	NULL
band	NULL
did	NULL
not	NULL
appear	NULL
until	NULL
approximately	NULL
15	NULL
min	NULL
after	NULL
treatment	NULL
with	NULL
IL-2	NULL
and	NULL
was	NULL
barely	NULL
detectable	NULL
by	NULL
60	NULL
min	NULL
.	NULL

The	NULL
phosphorylation	NULL
of	NULL
the	NULL
94-kDa	NULL
protein	NULL
could	NULL
be	NULL
detected	NULL
at	NULL
IL-2	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
0.5	NULL
unit/ml	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Maximal	NULL
activity	NULL
occurred	NULL
at	NULL
10	NULL
units/ml	NULL
and	NULL
did	NULL
not	NULL
change	NULL
at	NULL
IL-2	NULL
concentrations	NULL
as	NULL
high	NULL
as	NULL
1000	NULL
units/ml	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
NKL	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
four	NULL
proteins	NULL
recognized	NULL
by	NULL
anti-phospho-Stat1	NULL
were	NULL
members	NULL
of	NULL
the	NULL
Stat	NULL
family	NULL
,	NULL
antibodies	NULL
that	NULL
recognize	NULL
different	NULL
Stat	NULL
domains	NULL
were	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
Stat	NULL
proteins	NULL
from	NULL
IL-2-stimulated	NULL
cells	NULL
.	NULL

Once	NULL
immunoprecipitated	NULL
,	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
blotted	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
to	NULL
assess	NULL
the	NULL
phosphotyrosine	NULL
content	NULL
of	NULL
the	NULL
immunoprecipitated	NULL
proteins	NULL
Phospho-Ab	NULL
:	NULL
Stati	NULL
Stati	NULL
Ar	NULL
rales	NULL
.f	NULL
91	NULL
kDa	NULL
.	NULL

-	NULL
Nap	NULL
84	NULL
kDa	NULL
-	NULL
~	NULL
'pay	NULL
3°	NULL
.	NULL

4	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
SK-MEL-28	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
treated	NULL
for	NULL
15	NULL
min	NULL
with	NULL
IFN-a	NULL
(	NULL
1000	NULL
units	NULL
per	NULL
ml	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
were	NULL
separated	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
probed	NULL
with	NULL
antiserum	NULL
91/84	NULL
to	NULL
Statl	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
then	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-phospho-Stat1	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Ab	NULL
,	NULL
antibody	NULL
.	NULL

Biochemistry	NULL
:	NULL
Frank	NULL
et	NULL
al	NULL
.	NULL

A	NULL
Time	NULL
,	NULL
min	NULL
B	NULL
w	NULL
o	NULL
o	NULL
§	NULL
8	NULL
o	NULL
-	NULL
~-	NULL
®	NULL
©	NULL
~	NULL
®	NULL
u	NULL
o	NULL
o	NULL
-	NULL
pp95	NULL
``	NULL
*	NULL
*	NULL
``	NULL
~	NULL
~pp94	NULL
pp91	NULL
-	NULL
“	NULL
g	NULL
``	NULL
P	NULL
ppg1_	NULL
pp84	NULL
-	NULL
pp84	NULL
~	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

We	NULL
considered	NULL
whether	NULL
Stat1l	NULL
was	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
treatment	NULL
.	NULL

Immunoprecipitation	NULL
with	NULL
antibody	NULL
91C	NULL
,	NULL
which	NULL
recognizes	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
the	NULL
91-kDa	NULL
Statla	NULL
protein	NULL
(	NULL
amino	NULL
acids	NULL
713-738	NULL
)	NULL
followed	NULL
by	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
allowed	NULL
the	NULL
detection	NULL
in	NULL
IL-2-treated	NULL
NKL	NULL
cells	NULL
of	NULL
a	NULL
band	NULL
of	NULL
molecular	NULL
mass	NULL
92	NULL
kDa	NULL
that	NULL
is	NULL
identical	NULL
in	NULL
mobility	NULL
to	NULL
Statla	NULL
precipitated	NULL
from	NULL
IFN-a-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Given	NULL
this	NULL
finding	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
anti-phospho-Statl	NULL
antibodies	NULL
recognized	NULL
a	NULL
protein	NULL
of	NULL
identical	NULL
mobility	NULL
from	NULL
IL-2-treated	NULL
NKL	NULL
cells	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
Stat1	NULL
is	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Stat1	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
is	NULL
consistently	NULL
less	NULL
than	NULL
that	NULL
seen	NULL
with	NULL
stimulation	NULL
by	NULL
IFN-a	NULL
«	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
94-kDa	NULL
and	NULL
95-kDa	NULL
proteins	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
principal	NULL
Stats	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

We	NULL
next	NULL
considered	NULL
whether	NULL
Stat2	NULL
was	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

Immunoprecipitation	NULL
with	NULL
antibody	NULL
113	NULL
,	NULL
which	NULL
recognizes	NULL
a	NULL
unique	NULL
segment	NULL
of	NULL
Stat2	NULL
,	NULL
followed	NULL
by	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
revealed	NULL
a	NULL
113-kDa	NULL
band	NULL
from	NULL
IFN-a-treated	NULL
cells	NULL
that	NULL
represents	NULL
Stat2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
Statla	NULL
(	NULL
91	NULL
kDa	NULL
)	NULL
and	NULL
Stat1	NULL
$	NULL
B	NULL
(	NULL
84	NULL
kDa	NULL
)	NULL
were	NULL
coprecipitated	NULL
by	NULL
antibody	NULL
113	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
no	NULL
phos-photyrosine-containing	NULL
protein	NULL
was	NULL
immunoprecipitated	NULL
by	NULL
antibody	NULL
113	NULL
from	NULL
IL-2-treated	NULL
NKL	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
protein	NULL
is	NULL
not	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
Stat3	NULL
in	NULL
IL-2-induced	NULL
signaling	NULL
,	NULL
immunoprecipitation	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
antibody	NULL
91N	NULL
,	NULL
followed	NULL
by	NULL
blotting	NULL
with	NULL
the	NULL
anti-phosphotyrosine	NULL
antibody	NULL
.	NULL

The	NULL
91N	NULL
antibody	NULL
was	NULL
raised	NULL
to	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
Statl	NULL
(	NULL
amino	NULL
acids	NULL
2-66	NULL
)	NULL
,	NULL
a	NULL
region	NULL
that	NULL
is	NULL
highly	NULL
conserved	NULL
in	NULL
Stat3	NULL
(	NULL
24	NULL
)	NULL
.	NULL

This	NULL
antibody	NULL
can	NULL
immunoprecipitate	NULL
Stat1	NULL
only	NULL
weakly	NULL
,	NULL
but	NULL
it	NULL
is	NULL
very	NULL
effective	NULL
at	NULL
immuno-precipitating	NULL
Stat3	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Antibody	NULL
91N	NULL
precipitated	NULL
an	NULL
89-kDa	NULL
,	NULL
tyrosine-phosphorylated	NULL
protein	NULL
from	NULL
IL-2-treated	NULL
cells	NULL
that	NULL
represents	NULL
Stat3	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
signal	NULL
in	NULL
the	NULL
Stat3	NULL
immunoprecipitation	NULL
was	NULL
weak	NULL
,	NULL
it	NULL
was	NULL
reproducible	NULL
and	NULL
similar	NULL
in	NULL
magnitude	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
ciliary	NULL
neurotrophic	NULL
91C	NULL
-	NULL
giSsH2	NULL
-	NULL
113	NULL
3	NULL
¢	NULL
¢	NULL
Bd	NULL
bu	NULL
u	NULL
Ab	NULL
:	NULL
g1N	NULL
|	NULL
<	NULL
3	NULL
E	NULL
1	NULL
=	NULL
§	NULL
|	NULL
3	NULL
€	NULL
i	NULL
Cytokine	NULL
:	NULL
_	NULL
|	NULL
3	NULL
&	NULL
seee	NULL
-88	NULL
kDa-	NULL
t	NULL
wes	NULL
1	NULL
2	NULL
8	NULL
4	NULL
5	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
extracts	NULL
from	NULL
NKL	NULL
cells	NULL
followed	NULL
by	NULL
anti-phosphotyrosine	NULL
Western	NULL
blotting	NULL
.	NULL

Cells	NULL
were	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
IL-2	NULL
for	NULL
15	NULL
min	NULL
(	NULL
50	NULL
units/ml	NULL
;	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
11	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
IFN-a	NULL
for	NULL
15	NULL
min	NULL
(	NULL
500	NULL
units/ml	NULL
;	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Antibodies	NULL
(	NULL
Abs	NULL
)	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
were	NULL
raised	NULL
against	NULL
Statia	NULL
amino	NULL
acids	NULL
2-66	NULL
(	NULL
1N	NULL
;	NULL
lanes	NULL
1-3	NULL
)	NULL
,	NULL
amino	NULL
acids	NULL
713-738	NULL
(	NULL
91C	NULL
;	NULL
lanes	NULL
4-6	NULL
)	NULL
,	NULL
and	NULL
amino	NULL
acids	NULL
504-596	NULL
(	NULL
91SH2	NULL
;	NULL
lanes	NULL
7-9	NULL
)	NULL
and	NULL
against	NULL
Stat2	NULL
amino	NULL
acids	NULL
671-806	NULL
(	NULL
113	NULL
;	NULL
lanes	NULL
10-12	NULL
)	NULL
.	NULL

gues	NULL
“	NULL
_	NULL
‘	NULL
~-	NULL
<	NULL
ppg4	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
7781	NULL
IL-2	NULL
,	NULL
units/ml	NULL
o	NULL
FiG	NULL
.	NULL

2	NULL
.	NULL

Anti-phospho-Statl	NULL
o	NULL
g	NULL
3	NULL
L8	NULL
)	NULL
3	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PHA	NULL
for	NULL
12	NULL
days	NULL
and	NULL
treated	NULL
with	NULL
IL-2	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Dose-response	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
for	NULL
15	NULL
min	NULL
.	NULL

pp95	NULL
factor	NULL
stimulation	NULL
of	NULL
neuroblastoma	NULL
cells	NULL
(	NULL
29	NULL
)	NULL
.	NULL

No	NULL
such	NULL
protein	NULL
was	NULL
detected	NULL
in	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
anti-phospho-Stat1	NULL
antiserum	NULL
did	NULL
not	NULL
recognize	NULL
phosphorylated	NULL
Stat3	NULL
in	NULL
Western	NULL
blots	NULL
following	NULL
immunoprecipitation	NULL
with	NULL
antibody	NULL
91N	NULL
in	NULL
IL-2-treated	NULL
cells	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
anti-phospho-Stat1	NULL
antibodies	NULL
do	NULL
not	NULL
recognize	NULL
phosphorylated	NULL
Stats	NULL
in	NULL
general	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
IL-2	NULL
treatment	NULL
of	NULL
NKL	NULL
cells	NULL
or	NULL
PHA-stimulated	NULL
T	NULL
lymphocytes	NULL
leads	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Statl	NULL
and	NULL
Stat3	NULL
,	NULL
but	NULL
not	NULL
Stat2	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
94-	NULL
and	NULL
95-kDa	NULL
proteins	NULL
recognized	NULL
by	NULL
the	NULL
anti-phospho-Stat1l	NULL
antibodies	NULL
,	NULL
immunoprecipitation	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
antibody	NULL
91SH2	NULL
.	NULL

This	NULL
antibody	NULL
was	NULL
raised	NULL
against	NULL
amino	NULL
acids	NULL
504-596	NULL
of	NULL
Stat1	NULL
,	NULL
a	NULL
region	NULL
that	NULL
resembles	NULL
the	NULL
Src	NULL
homology	NULL
2	NULL
(	NULL
SH2	NULL
)	NULL
domain	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
91SH2	NULL
antibody	NULL
recognizes	NULL
Statl	NULL
in	NULL
Western	NULL
blots	NULL
,	NULL
but	NULL
it	NULL
is	NULL
unable	NULL
to	NULL
precipitate	NULL
Stat1	NULL
from	NULL
nondenatured	NULL
cell	NULL
extracts	NULL
.	NULL

This	NULL
antibody	NULL
did	NULL
not	NULL
precipitate	NULL
any	NULL
bands	NULL
from	NULL
nondenatured	NULL
extracts	NULL
of	NULL
IFN-	NULL
«	NULL
-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
antibody	NULL
91SH2	NULL
did	NULL
precipitate	NULL
from	NULL
IL-2-treated	NULL
NKL	NULL
cells	NULL
but	NULL
not	NULL
from	NULL
untreated	NULL
cells	NULL
proteins	NULL
of	NULL
94	NULL
and	NULL
95	NULL
kDa	NULL
that	NULL
were	NULL
detected	NULL
upon	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
94-	NULL
and	NULL
95-kDa	NULL
proteins	NULL
are	NULL
recognized	NULL
by	NULL
two	NULL
different	NULL
antibodies	NULL
that	NULL
bind	NULL
to	NULL
distinct	NULL
domains	NULL
on	NULL
Stat	NULL
proteins	NULL
(	NULL
the	NULL
SH2	NULL
domain	NULL
and	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
)	NULL
but	NULL
are	NULL
not	NULL
recognized	NULL
by	NULL
certain	NULL
anti-Stat1	NULL
antibodies	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
these	NULL
94-	NULL
and	NULL
95-kDa	NULL
proteins	NULL
may	NULL
be	NULL
members	NULL
of	NULL
the	NULL
Stat	NULL
family	NULL
distinct	NULL
from	NULL
Stat1	NULL
that	NULL
are	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
in	NULL
NKL	NULL
cells	NULL
.	NULL

Antibodies	NULL
to	NULL
Stat4	NULL
,	NULL
-5	NULL
,	NULL
and	NULL
-6	NULL
were	NULL
unable	NULL
to	NULL
immunoprecipitate	NULL
any	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
from	NULL
IL-2-treated	NULL
cells	NULL
,	NULL
although	NULL
'Western	NULL
analysis	NULL
using	NULL
specific	NULL
antibodies	NULL
indicated	NULL
that	NULL
all	NULL
three	NULL
of	NULL
these	NULL
Stat	NULL
proteins	NULL
are	NULL
present	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
p94	NULL
and	NULL
p95	NULL
represent	NULL
previously	NULL
Uescribed	NULL
Stat	NULL
proteins	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
94-	NULL
and	NULL
95-kDa	NULL
bands	NULL
represent	NULL
differentially	NULL
modified	NULL
forms	NULL
of	NULL
the	NULL
same	NULL
protein	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
using	NULL
extracts	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
.	NULL

On	NULL
Western	NULL
blots	NULL
with	NULL
anti-phospho-Stat1	NULL
antiserum	NULL
,	NULL
p94	NULL
appears	NULL
to	NULL
be	NULL
more	NULL
prominent	NULL
than	NULL
p95	NULL
in	NULL
IL-2-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Following	NULL
immunoprecipitation	NULL
with	NULL
the	NULL
91SH2	NULL
antibody	NULL
and	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
,	NULL
p95	NULL
often	NULL
appears	NULL
slightly	NULL
more	NULL
prominent	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
relative	NULL
affinities	NULL
of	NULL
the	NULL
anti-phospho-Stat1	NULL
antiserum	NULL
and	NULL
the	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
for	NULL
the	NULL
phosphorylation	NULL
sites	NULL
of	NULL
p94	NULL
and	NULL
p95	NULL
.	NULL

Alternatively	NULL
,	NULL
p95	NULL
may	NULL
have	NULL
other	NULL
phosphorylated	NULL
tyrosine	NULL
residues	NULL
in	NULL
addition	NULL
to	NULL
that	NULL
recognized	NULL
by	NULL
the	NULL
anti-phospho-Stat1	NULL
antiserum	NULL
,	NULL
and	NULL
this	NULL
may	NULL
lead	NULL
to	NULL
a	NULL
stronger	NULL
signal	NULL
on	NULL
the	NULL
anti-phosphotyrosine	NULL
Western	NULL
blot	NULL
.	NULL

Nuclear	NULL
Translocation	NULL
and	NULL
DNA	NULL
Binding	NULL
.	NULL

Upon	NULL
activation	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
Stat	NULL
proteins	NULL
may	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
can	NULL
bind	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
.	NULL

Cellular	NULL
fractionation	NULL
followed	NULL
by	NULL
anti-phospho-Stat1	NULL
Western	NULL
blotting	NULL
of	NULL
NKL	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
all	NULL
of	NULL
the	NULL
bands	NULL
identified	NULL
by	NULL
Western	NULL
blots	NULL
of	NULL
whole-cell	NULL
extracts	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Immunocytochemistry	NULL
with	NULL
the	NULL
anti-phospho-Stat1	NULL
antibody	NULL
also	NULL
revealed	NULL
nuclear	NULL
staining	NULL
of	NULL
NKL	NULL
cells	NULL
after	NULL
IL-2	NULL
treatment	NULL
,	NULL
but	NULL
not	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
finding	NULL
that	NULL
Jak	NULL
kinases	NULL
are	NULL
activated	NULL
in	NULL
the	NULL
cytoplasm	NULL
by	NULL
IL-2	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
unphos-	NULL
7782	NULL
Biochemistry	NULL
:	NULL
Frank	NULL
et	NULL
al	NULL
.	NULL

A	NULL
IL-2	NULL
:	NULL
=	NULL
+	NULL
«	NULL
0	NULL
«	NULL
G	NULL
»	NULL
3	NULL
~	NULL
3	NULL
o	NULL
Z2	NULL
0	NULL
Z	NULL
pp91-pas-	NULL
tas	NULL
1	NULL
2	NULL
3	NULL
4	NULL
B	NULL
Competitor	NULL
:	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
o.	NULL
Y	NULL
%	NULL
2	NULL
9	NULL
o	NULL
Z	NULL
c	NULL
a	NULL
Kb	NULL
y	NULL
2	NULL
2.2	NULL
som	NULL
m	NULL
s	NULL
1	NULL
_	NULL
.	NULL

~	NULL
o	NULL
a	NULL
a	NULL
m	NULL
m	NULL
m	NULL
m	NULL
.	NULL

IL-2	NULL
:	NULL
_-	NULL
+	NULL
+	NULL
§+	NULL
to	NULL
k	NULL
bok	NULL
&	NULL
40	NULL
12.35	NULL
455	NULL
1011	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Anti-phospho-Statl	NULL
Western	NULL
blot	NULL
of	NULL
cytoplasmic	NULL
(	NULL
Cyt	NULL
)	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
and	NULL
nuclear	NULL
(	NULL
Nuc	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
extracts	NULL
from	NULL
NKL	NULL
cells	NULL
that	NULL
were	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
for	NULL
10	NULL
min	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Electrophoretic	NULL
mobility-shift	NULL
assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
NKL	NULL
cells	NULL
that	NULL
had	NULL
either	NULL
been	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
for	NULL
10	NULL
min	NULL
;	NULL
lanes	NULL
2-11	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
*°P-labeled	NULL
probe	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Antibodies	NULL
(	NULL
Abs	NULL
)	NULL
were	NULL
included	NULL
in	NULL
the	NULL
binding	NULL
reactions	NULL
for	NULL
samples	NULL
in	NULL
lane	NULL
3	NULL
(	NULL
91C	NULL
)	NULL
,	NULL
lane	NULL
4	NULL
(	NULL
91N	NULL
)	NULL
,	NULL
lane	NULL
5	NULL
(	NULL
anti-phospho-Stat1	NULL
;	NULL
I1P	NULL
)	NULL
,	NULL
lane	NULL
6	NULL
(	NULL
91SH2	NULL
)	NULL
,	NULL
lane	NULL
7	NULL
(	NULL
Stat2	NULL
)	NULL
,	NULL
lane	NULL
8	NULL
(	NULL
Stat4	NULL
)	NULL
,	NULL
lane	NULL
9	NULL
(	NULL
Stat5	NULL
)	NULL
,	NULL
and	NULL
lane	NULL
10	NULL
(	NULL
Stat6	NULL
)	NULL
.	NULL

Lane	NULL
11	NULL
contained	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
the	NULL
unlabeled	NULL
DNA	NULL
probe	NULL
.	NULL

phorylated	NULL
Stat	NULL
proteins	NULL
are	NULL
located	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
other	NULL
systems	NULL
,	NULL
this	NULL
suggests	NULL
that	NULL
IL-2	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
translocation	NULL
of	NULL
Statla	NULL
,	NULL
Stat18	NULL
and	NULL
the	NULL
94-	NULL
and	NULL
95-kDa	NULL
proteins	NULL
.	NULL

This	NULL
ability	NULL
to	NULL
localize	NULL
in	NULL
the	NULL
nucleus	NULL
upon	NULL
tyrosine	NULL
phosphorylation	NULL
further	NULL
supports	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
94-and	NULL
95-kDa	NULL
proteins	NULL
are	NULL
Stat	NULL
family	NULL
members	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
Stat	NULL
proteins	NULL
to	NULL
bind	NULL
DNA	NULL
,	NULL
electrophoretic	NULL
mobility-shift	NULL
assays	NULL
were	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
probe	NULL
used	NULL
was	NULL
a	NULL
DNA	NULL
sequence	NULL
from	NULL
the	NULL
IFN-responsive	NULL
factor	NULL
1	NULL
gene	NULL
promoter	NULL
(	NULL
AGCCTGATTTCCCCGAAATGACGGC	NULL
)	NULL
(	NULL
31	NULL
)	NULL
that	NULL
can	NULL
bind	NULL
homodimers	NULL
of	NULL
Statl	NULL
«	NULL
,	NULL
homodimers	NULL
of	NULL
Stat3	NULL
,	NULL
and	NULL
heterodimers	NULL
of	NULL
Statla	NULL
and	NULL
Stat3	NULL
(	NULL
29	NULL
)	NULL
.	NULL

IL-2	NULL
treatment	NULL
of	NULL
NKL	NULL
cells	NULL
led	NULL
to	NULL
the	NULL
inducible	NULL
formation	NULL
of	NULL
three	NULL
complexes	NULL
bound	NULL
to	NULL
this	NULL
DNA	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
2	NULL
)	NULL
.	NULL

Small	NULL
amounts	NULL
of	NULL
these	NULL
complexes	NULL
were	NULL
detected	NULL
occasionally	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
could	NULL
be	NULL
abolished	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
unlabeled	NULL
DNA	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
represented	NULL
specific	NULL
binding	NULL
complexes	NULL
.	NULL

We	NULL
considered	NULL
whether	NULL
Stat1	NULL
a	NULL
was	NULL
a	NULL
component	NULL
of	NULL
one	NULL
of	NULL
these	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

Antibodies	NULL
specific	NULL
for	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
Stat1a	NULL
disrupted	NULL
complex	NULL
I	NULL
,	NULL
suggesting	NULL
that	NULL
Statla	NULL
is	NULL
present	NULL
in	NULL
this	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
Statl	NULL
that	NULL
also	NULL
recognize	NULL
Stat3	NULL
also	NULL
abolished	NULL
complex	NULL
I	NULL
and	NULL
,	NULL
in	NULL
addition	NULL
,	NULL
led	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
supershifted	NULL
complex	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
complex	NULL
inhibition	NULL
and	NULL
supershift	NULL
formation	NULL
by	NULL
these	NULL
antibodies	NULL
is	NULL
identical	NULL
to	NULL
that	NULL
seen	NULL
when	NULL
Statl	NULL
and	NULL
Stat3	NULL
are	NULL
bound	NULL
to	NULL
the	NULL
probe	NULL
(	NULL
29	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
participation	NULL
of	NULL
Stat3	NULL
in	NULL
the	NULL
binding	NULL
to	NULL
this	NULL
DNA	NULL
sequence	NULL
.	NULL

Anti-phospho-Stat1	NULL
antibodies	NULL
led	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
complexes	NULL
I	NULL
and	NULL
II	NULL
and	NULL
the	NULL
formation	NULL
of	NULL
supershifted	NULL
complex	NULL
C	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
one	NULL
or	NULL
more	NULL
proteins	NULL
recognized	NULL
by	NULL
anti-phospho-Stat1	NULL
were	NULL
present	NULL
in	NULL
complexes	NULL
I	NULL
and	NULL
II	NULL
,	NULL
although	NULL
Statl	NULL
itself	NULL
appeared	NULL
to	NULL
be	NULL
in	NULL
complex	NULL
III	NULL
.	NULL

Antibodies	NULL
to	NULL
the	NULL
SH2	NULL
domain	NULL
of	NULL
Stat1	NULL
led	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
supershifted	NULL
complex	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

This	NULL
antibody	NULL
does	NULL
not	NULL
supershift	NULL
complexes	NULL
from	NULL
IFN-a-treated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
Stat	NULL
proteins	NULL
other	NULL
than	NULL
Stati	NULL
that	NULL
are	NULL
recognized	NULL
by	NULL
this	NULL
antibody	NULL
are	NULL
bound	NULL
to	NULL
the	NULL
DNA	NULL
probe	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
results	NULL
suggest	NULL
that	NULL
p94	NULL
and/or	NULL
p95	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
present	NULL
in	NULL
protein-DNA	NULL
complexes	NULL
I	NULL
and	NULL
II	NULL
.	NULL

Antibodies	NULL
to	NULL
Stat2	NULL
,	NULL
-4	NULL
,	NULL
-5	NULL
,	NULL
and	NULL
-6	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
7-10	NULL
)	NULL
neither	NULL
inhibited	NULL
complex	NULL
formation	NULL
nor	NULL
supershifted	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
detected	NULL
in	NULL
IL-2-treated	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
Stat	NULL
proteins	NULL
were	NULL
not	NULL
present	NULL
in	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
Stat1	NULL
,	NULL
Stat3	NULL
,	NULL
and	NULL
the	NULL
two	NULL
Stat	NULL
proteins	NULL
p94	NULL
and	NULL
p95	NULL
not	NULL
only	NULL
become	NULL
phosphorylated	NULL
and	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
but	NULL
that	NULL
they	NULL
participate	NULL
in	NULL
specific	NULL
DNA-binding	NULL
complexes	NULL
,	NULL
as	NULL
well	NULL
.	NULL

Identical	NULL
findings	NULL
were	NULL
observed	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
DNA-binding	NULL
complexes	NULL
could	NULL
be	NULL
detected	NULL
with	NULL
a	NULL
probe	NULL
containing	NULL
a	NULL
consensus	NULL
IFN-y-activation	NULL
site	NULL
,	NULL
although	NULL
nonspecific	NULL
binding	NULL
to	NULL
that	NULL
probe	NULL
was	NULL
greater	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
interaction	NULL
of	NULL
IL-2	NULL
with	NULL
its	NULL
receptor	NULL
on	NULL
either	NULL
PHA-stimulated	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
or	NULL
on	NULL
an	NULL
NK	NULL
cell	NULL
line	NULL
leads	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
a	NULL
set	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

These	NULL
proteins	NULL
include	NULL
Statla	NULL
,	NULL
Stat1	NULL
$	NULL
B	NULL
,	NULL
and	NULL
Stat3	NULL
,	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
a	NULL
number	NULL
of	NULL
cytokines	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
two	NULL
other	NULL
proteins	NULL
of	NULL
molecular	NULL
masses	NULL
94	NULL
and	NULL
95	NULL
kDa	NULL
are	NULL
also	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
immunoprecipitation	NULL
experiments	NULL
,	NULL
these	NULL
proteins	NULL
share	NULL
antigenic	NULL
similarity	NULL
to	NULL
Stat	NULL
]	NULL
in	NULL
the	NULL
SH2	NULL
domain	NULL
,	NULL
and	NULL
from	NULL
the	NULL
Western-blotting	NULL
experiments	NULL
,	NULL
they	NULL
share	NULL
similarity	NULL
to	NULL
the	NULL
phosphorylation	NULL
site	NULL
of	NULL
Stat1	NULL
.	NULL

They	NULL
differ	NULL
from	NULL
Statl	NULL
,	NULL
however	NULL
,	NULL
in	NULL
their	NULL
mobility	NULL
on	NULL
SDS/polyacrylamide	NULL
gels	NULL
,	NULL
their	NULL
precipitation	NULL
by	NULL
antibodies	NULL
raised	NULL
to	NULL
the	NULL
SH2	NULL
domain	NULL
of	NULL
Stat1	NULL
,	NULL
their	NULL
lack	NULL
of	NULL
precipitation	NULL
by	NULL
antibodies	NULL
raised	NULL
to	NULL
the	NULL
carboxyl	NULL
terminus	NULL
of	NULL
Statl	NULL
,	NULL
and	NULL
their	NULL
distinct	NULL
characteristics	NULL
in	NULL
DNA-binding	NULL
assays	NULL
.	NULL

Three	NULL
Stat	NULL
proteins	NULL
have	NULL
been	NULL
described	NULL
recently	NULL
,	NULL
and	NULL
we	NULL
considered	NULL
whether	NULL
p94	NULL
and	NULL
p95	NULL
could	NULL
be	NULL
Stat4	NULL
,	NULL
Stat5	NULL
,	NULL
or	NULL
Stat6	NULL
(	NULL
26-28	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
Stat4	NULL
,	NULL
-5	NULL
,	NULL
and	NULL
-6	NULL
did	NULL
not	NULL
immunoprecipitate	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
from	NULL
IL-2-treated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
nor	NULL
did	NULL
they	NULL
alter	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
IL-2-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
p94	NULL
and	NULL
p95	NULL
may	NULL
be	NULL
members	NULL
of	NULL
the	NULL
Stat	NULL
family	NULL
,	NULL
though	NULL
p94	NULL
and	NULL
p95	NULL
may	NULL
be	NULL
differentially	NULL
modified	NULL
forms	NULL
of	NULL
the	NULL
same	NULL
protein	NULL
.	NULL

p94	NULL
and	NULL
p95	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
predominant	NULL
Stat	NULL
proteins	NULL
phosphorylated	NULL
in	NULL
T	NULL
lymphocytes	NULL
or	NULL
NK	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
and	NULL
may	NULL
have	NULL
a	NULL
major	NULL
role	NULL
in	NULL
determining	NULL
the	NULL
genes	NULL
that	NULL
are	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

Given	NULL
that	NULL
multiple	NULL
cytokines	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
Jak	NULL
kinases	NULL
and	NULL
the	NULL
phosphorylation	NULL
of	NULL
Stat	NULL
proteins	NULL
,	NULL
a	NULL
key	NULL
question	NULL
concerns	NULL
how	NULL
a	NULL
cytokine	NULL
leads	NULL
to	NULL
specific	NULL
responses	NULL
in	NULL
a	NULL
particular	NULL
cell	NULL
.	NULL

Multiple	NULL
levels	NULL
of	NULL
control	NULL
can	NULL
be	NULL
envisioned	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
particular	NULL
ligand-binding	NULL
a	NULL
chain	NULL
on	NULL
a	NULL
cell	NULL
will	NULL
determine	NULL
if	NULL
its	NULL
cognate	NULL
cytokine	NULL
will	NULL
bind	NULL
to	NULL
that	NULL
cell	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
particular	NULL
B	NULL
and	NULL
y	NULL
subunits	NULL
that	NULL
can	NULL
interact	NULL
with	NULL
a	NULL
specific	NULL
a	NULL
chain	NULL
may	NULL
determine	NULL
which	NULL
Jak	NULL
kinases	NULL
are	NULL
activated	NULL
by	NULL
cytokine	NULL
binding	NULL
.	NULL

The	NULL
individual	NULL
Jak	NULL
kinase	NULL
family	NULL
members	NULL
may	NULL
have	NULL
restricted	NULL
specificity	NULL
in	NULL
terms	NULL
of	NULL
Stat	NULL
proteins	NULL
that	NULL
they	NULL
can	NULL
phosphorylate	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
p94	NULL
and	NULL
p95	NULL
which	NULL
occurs	NULL
after	NULL
IL-2	NULL
treatment	NULL
does	NULL
not	NULL
occur	NULL
in	NULL
response	NULL
to	NULL
IFN-	NULL
«	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
the	NULL
specificity	NULL
of	NULL
Jak-3	NULL
,	NULL
which	NULL
is	NULL
not	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IFN-a	NULL
but	NULL
is	NULL
activated	NULL
by	NULL
IL-2	NULL
.	NULL

Alternatively	NULL
,	NULL
particular	NULL
Stat	NULL
proteins	NULL
Biochemistry	NULL
:	NULL
Frank	NULL
et	NULL
al	NULL
.	NULL

may	NULL
only	NULL
be	NULL
expressed	NULL
in	NULL
a	NULL
cell-specific	NULL
manner	NULL
,	NULL
allowing	NULL
a	NULL
given	NULL
cytokine	NULL
to	NULL
have	NULL
distinct	NULL
effects	NULL
in	NULL
different	NULL
cells	NULL
.	NULL

This	NULL
would	NULL
also	NULL
generate	NULL
a	NULL
greater	NULL
diversity	NULL
of	NULL
responses	NULL
from	NULL
the	NULL
small	NULL
number	NULL
of	NULL
Jak	NULL
kinases	NULL
that	NULL
have	NULL
been	NULL
identified	NULL
thus	NULL
far	NULL
.	NULL

There	NULL
is	NULL
evidence	NULL
that	NULL
Stat	NULL
proteins	NULL
bind	NULL
to	NULL
DNA	NULL
as	NULL
dimers	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
specific	NULL
combination	NULL
of	NULL
Stat	NULL
proteins	NULL
that	NULL
become	NULL
phosphorylated	NULL
at	NULL
a	NULL
given	NULL
time	NULL
will	NULL
likely	NULL
determine	NULL
the	NULL
particular	NULL
target	NULL
genes	NULL
that	NULL
become	NULL
activated	NULL
.	NULL

Finally	NULL
,	NULL
cell-or	NULL
tissue-specific	NULL
restriction	NULL
of	NULL
other	NULL
regulators	NULL
of	NULL
gene	NULL
acti-vation	NULL
,	NULL
such	NULL
as	NULL
transcription	NULL
factors	NULL
that	NULL
may	NULL
function	NULL
in	NULL
concert	NULL
with	NULL
Stat	NULL
proteins	NULL
or	NULL
the	NULL
methylation	NULL
of	NULL
particular	NULL
genes	NULL
,	NULL
may	NULL
control	NULL
cell-specific	NULL
responses	NULL
to	NULL
a	NULL
given	NULL
cytokine	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
B	NULL
and	NULL
y	NULL
subunits	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
interact	NULL
with	NULL
Jak-1	NULL
and	NULL
Jak-3	NULL
,	NULL
respectively	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
known	NULL
that	NULL
heterodimerization	NULL
of	NULL
the	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
is	NULL
necessary	NULL
for	NULL
IL-2	NULL
signaling	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
IL-2	NULL
induces	NULL
dimerization	NULL
of	NULL
the	NULL
B	NULL
and	NULL
y	NULL
subunits	NULL
,	NULL
leading	NULL
to	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Jak-1	NULL
and	NULL
Jak-3	NULL
.	NULL

The	NULL
present	NULL
study	NULL
provides	NULL
evidence	NULL
for	NULL
the	NULL
subsequent	NULL
steps	NULL
of	NULL
IL-2-induced	NULL
signal	NULL
transduction	NULL
.	NULL

Five	NULL
Stat	NULL
proteins-Stat1a	NULL
,	NULL
Stat1f	NULL
,	NULL
Stat3	NULL
,	NULL
and	NULL
the	NULL
Stat	NULL
proteins	NULL
described	NULL
here	NULL
,	NULL
p94	NULL
and	NULL
p95-are	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
and	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
they	NULL
can	NULL
bind	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
and	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
genes	NULL
that	NULL
contain	NULL
these	NULL
DNA	NULL
sequences	NULL
within	NULL
their	NULL
promoter	NULL
.	NULL

That	NULL
each	NULL
of	NULL
these	NULL
five	NULL
proteins	NULL
has	NULL
distinct	NULL
kinetics	NULL
of	NULL
phosphorylation	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
different	NULL
DNA-binding	NULL
complexes	NULL
may	NULL
form	NULL
over	NULL
time	NULL
.	NULL

This	NULL
may	NULL
allow	NULL
these	NULL
proteins	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
sequential	NULL
activation	NULL
of	NULL
genes	NULL
over	NULL
many	NULL
hours	NULL
following	NULL
stimulation	NULL
by	NULL
IL-2	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
c-fos	NULL
protooncogene	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
serum-response	NULL
element	NULL
can	NULL
mediate	NULL
IL-2-induced	NULL
gene	NULL
activation	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
present	NULL
study	NULL
suggests	NULL
that	NULL
DNA	NULL
sequences	NULL
to	NULL
which	NULL
Stat	NULL
proteins	NULL
can	NULL
bind	NULL
also	NULL
may	NULL
be	NULL
important	NULL
for	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
Stat	NULL
proteins	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
will	NULL
allow	NULL
a	NULL
further	NULL
analysis	NULL
of	NULL
the	NULL
physiological	NULL
effects	NULL
of	NULL
this	NULL
cytokine	NULL
,	NULL
including	NULL
the	NULL
identification	NULL
of	NULL
genes	NULL
that	NULL
are	NULL
transcriptionally	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

Such	NULL
knowledge	NULL
may	NULL
shed	NULL
light	NULL
on	NULL
T-cell	NULL
and	NULL
NK-cell	NULL
activation	NULL
and	NULL
prolifer-ation	NULL
,	NULL
as	NULL
well	NULL
as	NULL
on	NULL
defects	NULL
in	NULL
lymphocyte	NULL
signaling	NULL
.	NULL

It	NULL
is	NULL
already	NULL
known	NULL
that	NULL
at	NULL
least	NULL
one	NULL
form	NULL
of	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
in	NULL
humans	NULL
,	NULL
in	NULL
which	NULL
there	NULL
is	NULL
diminished	NULL
lymphocyte	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
y	NULL
subunit	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
that	NULL
decreases	NULL
the	NULL
association	NULL
of	NULL
this	NULL
subunit	NULL
with	NULL
Jak-3	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
also	NULL
suggests	NULL
that	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-7	NULL
,	NULL
all	NULL
of	NULL
which	NULL
share	NULL
a	NULL
common	NULL
y	NULL
chain	NULL
in	NULL
their	NULL
receptors	NULL
and	NULL
activate	NULL
Jak-3	NULL
,	NULL
may	NULL
prevent	NULL
the	NULL
induction	NULL
of	NULL
anergy	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
understanding	NULL
these	NULL
signaling	NULL
components	NULL
may	NULL
shed	NULL
light	NULL
on	NULL
such	NULL
processes	NULL
as	NULL
immunodeficiency	NULL
states	NULL
,	NULL
immune	NULL
suppression	NULL
,	NULL
and	NULL
lym-phoid	NULL
malignancies	NULL
.	NULL

We	NULL
thank	NULL
Chris	NULL
Schindler	NULL
for	NULL
thoughtful	NULL
advice	NULL
and	NULL
anti-Stat	NULL
antibodies	NULL
,	NULL
and	NULL
Christine	NULL
Cameron	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
Physician	NULL
Research	NULL
Fellowship	NULL
(	NULL
D.A.F	NULL
.	NULL
)	NULL

,	NULL
a	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
Fellowship	NULL
(	NULL
A.B	NULL
.	NULL
)	NULL

,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
CA41619	NULL
(	NULL
J.R.	NULL
)	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Grant	NULL
CA43855	NULL
,	NULL
and	NULL
an	NULL
American	NULL
Cancer	NULL
Society	NULL
Faculty	NULL
Research	NULL
Award	NULL
FRA-379	NULL
(	NULL
M.E.G	NULL
.	NULL
)	NULL

.	NULL

1	NULL
.	NULL

Morgan	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
&	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1976	NULL
)	NULL
Science	NULL
193	NULL
,	NULL
1007-1008	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Asao	NULL
,	NULL
H.	NULL
,	NULL
Ohtani	NULL
,	NULL
K.	NULL
,	NULL
Ishii	NULL
,	NULL
N.	NULL
,	NULL
Kumaki	NULL
,	NULL
S.	NULL
,	NULL
Tanaka	NULL
,	NULL
N.	NULL
,	NULL
Munakata	NULL
,	NULL
H.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
&	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
379-382	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Nakamura	NULL
,	NULL
Y.	NULL
,	NULL
Russell	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Mess	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Friedmann	NULL
,	NULL
M.	NULL
,	NULL
Erdos	NULL
,	NULL
M.	NULL
,	NULL
Francois	NULL
,	NULL
C.	NULL
,	NULL
Jacques	NULL
,	NULL
Y.	NULL
,	NULL
Adelstein	NULL
,	NULL
S.	NULL
&	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
369	NULL
,	NULL
330-333	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
7783	NULL
Nelson	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Lord	NULL
,	NULL
J.	NULL
D.	NULL
&	NULL
Greenberg	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
369	NULL
,	NULL
333-336	NULL
.	NULL

Truitt	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Mills	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Turck	NULL
,	NULL
C.	NULL
W.	NULL
&	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
5937-5943	NULL
.	NULL

Evans	NULL
,	NULL
S.	NULL
W.	NULL
&	NULL
Farrar	NULL
,	NULL
W.	NULL
L.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
4624-4630	NULL
.	NULL

Kuo	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Chung	NULL
,	NULL
J.	NULL
,	NULL
Fiorentino	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Blenis	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
358	NULL
,	NULL
70-73	NULL
.	NULL

Horak	NULL
,	NULL
I.	NULL
D.	NULL
,	NULL
Gress	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Lucas	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Horak	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Waidmann	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

&	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
1996-2000	NULL
.	NULL

Torigoe	NULL
,	NULL
T.	NULL
,	NULL
Saragovi	NULL
,	NULL
H.	NULL
U	NULL
.	NULL

&	NULL
Reed	NULL
,	NULL
J.C.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
2674-2678	NULL
.	NULL

Satoh	NULL
,	NULL
T.	NULL
,	NULL
Nakafuku	NULL
,	NULL
M.	NULL
,	NULL
Miyajima	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Kaziro	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
3314-3318	NULL
.	NULL

Turner	NULL
,	NULL
B.	NULL
,	NULL
Rapp	NULL
,	NULL
U.	NULL
,	NULL
App	NULL
,	NULL
H.	NULL
,	NULL
Greene	NULL
,	NULL
M.	NULL
,	NULL
Dobashi	NULL
,	NULL
K.	NULL
&	NULL
Reed	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
1227-1231	NULL
.	NULL

Zmuidzinas	NULL
,	NULL
A.	NULL
,	NULL
Mamon	NULL
,	NULL
H.	NULL
,	NULL
Roberts	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2794-2803	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Sabath	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Hoover	NULL
,	NULL
R.	NULL
G.	NULL
&	NULL
Prystowsky	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5	NULL
,	NULL
3361-3368	NULL
.	NULL

Stern	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Science	NULL
233	NULL
,	NULL
203-206	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Yoneyama	NULL
,	NULL
M.	NULL
,	NULL
Tsuji	NULL
,	NULL
J.	NULL
,	NULL
Matsumoto	NULL
,	NULL
K.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
57-67	NULL
.	NULL

Cosman	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Cytokine	NULL
5	NULL
,	NULL
96-106	NULL
.	NULL

Johnston	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kawamura	NULL
,	NULL
M.	NULL
,	NULL
Kirken	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
Y.-Q	NULL
.	NULL

,	NULL
Blake	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
Shibuya	NULL
,	NULL
K.	NULL
,	NULL
Ortaldo	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
&	NULL
O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
370	NULL
,	NULL
151-153	NULL
.	NULL

Kawamura	NULL
,	NULL
M.	NULL
;	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Johnston	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Blake	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
Chen	NULL
,	NULL
Y.-Q	NULL
.	NULL

,	NULL
Lal	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
Lloyd	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Kelvin	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Staples	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Ortaldo	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
6374-6378	NULL
.	NULL

Witthuhn	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Silveennoinen	NULL
,	NULL
O.	NULL
,	NULL
Miura	NULL
,	NULL
O.	NULL
,	NULL
Lai	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Cwik	NULL
,	NULL
C.	NULL
,	NULL
Liu	NULL
,	NULL
E.	NULL
T.	NULL
&	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
370	NULL
,	NULL
153-157	NULL
.	NULL

Schindler	NULL
,	NULL
C.	NULL
,	NULL
Shuai	NULL
,	NULL
K.	NULL
,	NULL
Prezioso	NULL
,	NULL
V.	NULL
R.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
809-813	NULL
.	NULL

Shuai	NULL
,	NULL
K.	NULL
,	NULL
Schindler	NULL
,	NULL
C.	NULL
,	NULL
Prezioso	NULL
,	NULL
V.	NULL
R.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
1808-1812	NULL
.	NULL

Schindler	NULL
,	NULL
C.	NULL
,	NULL
Fu	NULL
,	NULL
X.-Y	NULL
.	NULL

,	NULL
Improta	NULL
,	NULL
T.	NULL
,	NULL
Aebersold	NULL
,	NULL
R.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
7836-7839	NULL
.	NULL

Shuai	NULL
,	NULL
K.	NULL
,	NULL
Stark	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Kerr	NULL
,	NULL
I.	NULL
M.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
261	NULL
,	NULL
1744-1746	NULL
.	NULL

Akira	NULL
,	NULL
S.	NULL
,	NULL
Nishio	NULL
,	NULL
Y.	NULL
,	NULL
Inoue	NULL
,	NULL
M.	NULL
,	NULL
Wang	NULL
,	NULL
X.-J	NULL
.	NULL

,	NULL
Wei	NULL
,	NULL
S.	NULL
,	NULL
Matsusaka	NULL
,	NULL
T.	NULL
,	NULL
Yoshida	NULL
,	NULL
K.	NULL
,	NULL
Sudo	NULL
,	NULL
T.	NULL
,	NULL
Naruto	NULL
,	NULL
M.	NULL
&	NULL
Kishimoto	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
77	NULL
,	NULL
63-71	NULL
.	NULL

Zhong	NULL
,	NULL
Z.	NULL
,	NULL
Wen	NULL
,	NULL
Z	NULL
.	NULL

&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
4806-4810	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
,	NULL
Quelle	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Thierfelder	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Kreider	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Gilbert	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Jenkins	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
Silvennoinen	NULL
,	NULL
O	NULL
.	NULL

&	NULL
Thle	NULL
,	NULL
J.	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
4342-4349	NULL
.	NULL

Gouilleux	NULL
,	NULL
F.	NULL
,	NULL
Wakao	NULL
,	NULL
H.	NULL
,	NULL
Mundt	NULL
,	NULL
M.	NULL
&	NULL
Groner	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
4361-4369	NULL
.	NULL

Hou	NULL
,	NULL
J.	NULL
,	NULL
Schindler	NULL
,	NULL
U.	NULL
,	NULL
Henzel	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Ho	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
Brasseur	NULL
,	NULL
M.	NULL
&	NULL
McKnight	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
265	NULL
,	NULL
1701-1706	NULL
.	NULL

Bonni	NULL
,	NULL
A.	NULL
,	NULL
Frank	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Schindler	NULL
,	NULL
C.	NULL
&	NULL
Greenberg	NULL
,	NULL
M.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
1575-1579	NULL
.	NULL

Koch	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Anderson	NULL
,	NULL
D.	NULL
,	NULL
Morgan	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Ellis	NULL
,	NULL
C.	NULL
&	NULL
Pawson	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
252	NULL
,	NULL
668-674	NULL
.	NULL

Lew	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Decker	NULL
,	NULL
T.	NULL
,	NULL
Strehlow	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
182-191	NULL
.	NULL

Shuai	NULL
,	NULL
K.	NULL
,	NULL
Horvath	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Huang	NULL
,	NULL
L.	NULL
H.	NULL
T.	NULL
,	NULL
Qureshi	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Cowburn	NULL
,	NULL
D.	NULL
&	NULL
Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
821-828	NULL
.	NULL

Russell	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Johnston	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Noguchi	NULL
,	NULL
M.	NULL
,	NULL
Kawamura	NULL
,	NULL
M.	NULL
,	NULL
Bacon	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Friedmann	NULL
,	NULL
M.	NULL
,	NULL
Berg	NULL
,	NULL
M.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Witthuhn	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
,	NULL
Goldman	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Schmarstieg	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

&	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1042-1045	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Fujii	NULL
,	NULL
H.	NULL
,	NULL
Nakagawa	NULL
,	NULL
Y.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Liu	NULL
,	NULL
Z.-J	NULL
.	NULL

,	NULL
Oishi	NULL
,	NULL
I.	NULL
,	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
,	NULL
Witthuhn	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1045-1047	NULL
.	NULL

Trouche	NULL
,	NULL
D.	NULL
,	NULL
Robin	NULL
,	NULL
P.	NULL
,	NULL
Robillard	NULL
,	NULL
O.	NULL
,	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
&	NULL
Harel-Bellan	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
2398-2403	NULL
.	NULL

Boussiotis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Barber	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Nakari	NULL
,	NULL
T.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Bernstein	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
D'Andrea	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Nadler	NULL
,	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1039-1042	NULL
.	NULL

Robertson	NULL
,	NULL
M.J.	NULL
,	NULL
Cochran	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Cameron	NULL
,	NULL
C.	NULL
,	NULL
Le	NULL
,	NULL
J.-M.	NULL
,	NULL
Tantravahi	NULL
,	NULL
R.	NULL
&	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Exp	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

